Chris Horan, Artiva’s Chief Technical Operations Officer, talks with BioProcess Insider about why decreased risk and inexpensive manufacturing might give allogeneic natural killer (NK) cell therapies the edge over chimeric antigen receptors (CAR)-T therapies. Read the article here. The post BioProcess Insider: Artiva Discusses Scalable NK Cells to Treat Autoimmune Diseases appeared first on Artiva Biotherapeutics.
